Lifitegrast

Lifitegrast
Clinical data
Trade names	Xiidra
Other names	SAR-1118
AHFS/Drugs.com	Monograph
MedlinePlus	a616039
Pregnancy; category	AU: B1;
Routes of; administration	Eye drops
ATC code	S01XA25 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name N-{[2-(1-Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl}-3-(methylsulfonyl)-L-phenylalanine;
CAS Number	1025967-78-5;
PubChem CID	11965427;
DrugBank	DB11611;
ChemSpider	10139520;
UNII	038E5L962W;
KEGG	D10374;
ChEBI	CHEBI:133023 ;
ChEMBL	ChEMBL2048028;
CompTox Dashboard (EPA)	DTXSID60145345 ;
ECHA InfoCard	100.245.695
Chemical and physical data
Formula	C29H24Cl2N2O7S
Molar mass	615.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CS(=O)(=O)c1cccc(c1)C[C@@H](C(=O)O)NC(=O)c2c(cc3c(c2Cl)CCN(C3)C(=O)c4ccc5ccoc5c4)Cl;
	InChI InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1; Key:JFOZKMSJYSPYLN-QHCPKHFHSA-N;

Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding. It is often used as an alternative to ciclosporin (Ikervis, Restasis, Vevye, Verkazia or Cequa) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye.